Esperion Therapeutics, Inc. (ESPR) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.05. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ESPR = $9 (+339% upside).
Valuation: ESPR trades at a trailing Price-to-Earnings (P/E) of -24 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.84.
Financials: revenue is $403M, +87%/yr average growth. Net income is $23M (loss), growing at +52.9%/yr. Net profit margin is -5.6% (negative). Gross margin is 67.9% (+3.6 pp trend).
Balance sheet: total debt is $548M with negative equity of -$302M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.56 (tight liquidity). Debt-to-assets is 117.6%. Total assets: $466M.
Analyst outlook: 10 / 25 analysts rate ESPR as buy (40%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 0/100 (Fail), Moat 58/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
